Research Update: KazInvestBank 'B-/C' Ratings Affirmed On Bank Criteria Change; Outlook Remains Negative Dec 11

  • ID: 2031016
  • December 2011
  • Standard & Poors
1 of 3

Following a review of KazInvestBank (KIB) under Standard & Poor's revised bank criteria (published on Nov. 9, 2011), we have affirmed our 'B-/C' ratings and 'kzBB-' Kazakhstan national scale rating on the bank. The outlook remains negative. Our ratings on KIB reflect the bank's 'bb-' anchor, as well as its weak business position, moderate capital and earnings, moderate risk position, average funding, and adequate liquidity. In our view, KIB's business and financial profiles remain vulnerable to the still challenging operating conditions. As we previously announced, on Dec. 12, 2011, Standard & Poor's Ratings Services affirmed its 'B-/C' long- and short-term issuer credit ratings and its 'kzBB-' Kazakhstan national scale rating on KazInvestBank (KIB). The outlook remains negative. The ratings on...

Companies mentioned in this report are: KazInvestBank
Action: Affirmed

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Product Type: Research Update
Research updates complement media releases. They offer more depth and detail than summary analyses by incorporating all information published in the media release. They are more up to date than summaries in that they are published simultaneously with media releases.

Note: Product cover images may vary from those shown
2 of 3


Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.